{"schema_version":"secwatch.filing_event.v1","accession":"0001649094-25-000112","form_type":"8-K","ticker":"PCVX","cik":"0001649094","company_name":"Vaxcyte, Inc.","filed_at":"2025-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.040942+00:00","generated_at":"2026-05-17T00:38:52.331543+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Vaxcyte Q3 net loss $212.8M; cash $2.67B; VAX-31 adult pivotal study start Dec 2025","bullets":["Net loss of $212.8M for Q3 2025 vs $103.1M in Q3 2024; R&D expenses $209.9M, up from $116.9M.","Cash, cash equivalents and investments $2.67B as of Sept 30, 2025, expected to fund operations into mid-2028.","Final VAX-24 infant Phase 2 data show robust dose-dependent immune responses, validating higher VAX-31 doses.","VAX-31 adult pivotal non-inferiority study to start Dec 2025; topline data expected in 2026.","Up to $1B fill-finish agreement with Thermo Fisher in North Carolina for long-term U.S. commercial supply."],"urls":{"canonical":"https://secwatch.observer/filing/0001649094-25-000112","json":"https://secwatch.observer/filing/0001649094-25-000112.json","markdown":"https://secwatch.observer/filing/0001649094-25-000112.md","text":"https://secwatch.observer/filing/0001649094-25-000112.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649094/000164909425000112/0001649094-25-000112-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649094/000164909425000112/pcvx-20251104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:38:52.331543+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}